Bromo-deaza-SAH: A potent and selective DOT1L inhibitor
Chemical inhibition of proteins involved in chromatin-mediated signaling is an emerging strategy to control chromatin compaction with the aim to reprogram expression networks to alter disease states. Protein methyltransferases constitute one of the protein families that participate in epigenetic con...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1797074563336503296 |
|---|---|
| author | Yu, W Smil, D Li, F Tempel, W Fedorov, O Nguyen, K Bolshan, Y Al-Awar, R Knapp, S Arrowsmith, C Vedadi, M Brown, P Schapira, M |
| author_facet | Yu, W Smil, D Li, F Tempel, W Fedorov, O Nguyen, K Bolshan, Y Al-Awar, R Knapp, S Arrowsmith, C Vedadi, M Brown, P Schapira, M |
| author_sort | Yu, W |
| collection | OXFORD |
| description | Chemical inhibition of proteins involved in chromatin-mediated signaling is an emerging strategy to control chromatin compaction with the aim to reprogram expression networks to alter disease states. Protein methyltransferases constitute one of the protein families that participate in epigenetic control of gene expression, and represent a novel therapeutic target class. Recruitment of the protein lysine methyltransferase DOT1L at aberrant loci is a frequent mechanism driving acute lymphoid and myeloid leukemias, particularly in infants, and pharmacological inhibition of DOT1L extends survival in a mouse model of mixed lineage leukemia. A better understanding of the structural chemistry of DOT1L inhibition would accelerate the development of improved compounds. Here, we report that the addition of a single halogen atom at a critical position in the cofactor product S-adenosylhomocysteine (SAH, an inhibitor of SAM-dependent methyltransferases) results in an 8-fold increase in potency against DOT1L, and reduced activities against other protein and non-protein methyltransferases. We solved the crystal structure of DOT1L in complex with Bromo-deaza-SAH and rationalized the observed effects. This discovery reveals a simple strategy to engineer selectivity and potency towards DOT1L into the adenosine scaffold of the cofactor shared by all methyltransferases, and can be exploited towards the development of clinical candidates against mixed lineage leukemia. © 2013 Elsevier Ltd. All rights reserved. |
| first_indexed | 2024-03-06T23:38:01Z |
| format | Journal article |
| id | oxford-uuid:6e538ffa-8265-4019-8a26-8e6f5d74e5dd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:38:01Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:6e538ffa-8265-4019-8a26-8e6f5d74e5dd2022-03-26T19:23:47ZBromo-deaza-SAH: A potent and selective DOT1L inhibitorJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6e538ffa-8265-4019-8a26-8e6f5d74e5ddEnglishSymplectic Elements at Oxford2013Yu, WSmil, DLi, FTempel, WFedorov, ONguyen, KBolshan, YAl-Awar, RKnapp, SArrowsmith, CVedadi, MBrown, PSchapira, MChemical inhibition of proteins involved in chromatin-mediated signaling is an emerging strategy to control chromatin compaction with the aim to reprogram expression networks to alter disease states. Protein methyltransferases constitute one of the protein families that participate in epigenetic control of gene expression, and represent a novel therapeutic target class. Recruitment of the protein lysine methyltransferase DOT1L at aberrant loci is a frequent mechanism driving acute lymphoid and myeloid leukemias, particularly in infants, and pharmacological inhibition of DOT1L extends survival in a mouse model of mixed lineage leukemia. A better understanding of the structural chemistry of DOT1L inhibition would accelerate the development of improved compounds. Here, we report that the addition of a single halogen atom at a critical position in the cofactor product S-adenosylhomocysteine (SAH, an inhibitor of SAM-dependent methyltransferases) results in an 8-fold increase in potency against DOT1L, and reduced activities against other protein and non-protein methyltransferases. We solved the crystal structure of DOT1L in complex with Bromo-deaza-SAH and rationalized the observed effects. This discovery reveals a simple strategy to engineer selectivity and potency towards DOT1L into the adenosine scaffold of the cofactor shared by all methyltransferases, and can be exploited towards the development of clinical candidates against mixed lineage leukemia. © 2013 Elsevier Ltd. All rights reserved. |
| spellingShingle | Yu, W Smil, D Li, F Tempel, W Fedorov, O Nguyen, K Bolshan, Y Al-Awar, R Knapp, S Arrowsmith, C Vedadi, M Brown, P Schapira, M Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title | Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title_full | Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title_fullStr | Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title_full_unstemmed | Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title_short | Bromo-deaza-SAH: A potent and selective DOT1L inhibitor |
| title_sort | bromo deaza sah a potent and selective dot1l inhibitor |
| work_keys_str_mv | AT yuw bromodeazasahapotentandselectivedot1linhibitor AT smild bromodeazasahapotentandselectivedot1linhibitor AT lif bromodeazasahapotentandselectivedot1linhibitor AT tempelw bromodeazasahapotentandselectivedot1linhibitor AT fedorovo bromodeazasahapotentandselectivedot1linhibitor AT nguyenk bromodeazasahapotentandselectivedot1linhibitor AT bolshany bromodeazasahapotentandselectivedot1linhibitor AT alawarr bromodeazasahapotentandselectivedot1linhibitor AT knapps bromodeazasahapotentandselectivedot1linhibitor AT arrowsmithc bromodeazasahapotentandselectivedot1linhibitor AT vedadim bromodeazasahapotentandselectivedot1linhibitor AT brownp bromodeazasahapotentandselectivedot1linhibitor AT schapiram bromodeazasahapotentandselectivedot1linhibitor |